Rujia Xie

Author PubWeight™ 8.47^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Irinotecan pathway genotype analysis to predict pharmacokinetics.	Clin Cancer Res	2003	1.42
2	A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.	Br J Clin Pharmacol	2005	1.28
3	Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH.	Eur J Endocrinol	2009	1.16
4	Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.	Br J Clin Pharmacol	2005	1.09
5	Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.	Clin Cancer Res	2004	0.96
6	Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.	Pharm Res	2006	0.94
7	Zinc supplementation partially prevents renal pathological changes in diabetic rats.	J Nutr Biochem	2009	0.89
8	Pharmacokinetic/pharmacodynamic modelling in oncological drug development.	Basic Clin Pharmacol Toxicol	2005	0.89